Exhibit 99.1 Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights — London, March 28, 2023 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the year ended December 31, 2022 and provided an update on recent corporate highlights. “In 2022, we made important progress in the ongoing advancement of our core rare disease programs. The data from our Phase 2 ...

| --- | --- | --- | --- | |---------------------------------------------------------------------|-------------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | Unlocking the potential of novel targets for cancer and rare diseases | | | | M e r e o B i o P h a r m a G r o u p p l c N A S D A Q : M R E O | S e p t e m b e r 2 0 2 1 | | | Disclaimer This presentation has been prepared by Mereo BioPharma Group plc (the "Company") solely for your information an ...

Mereo BioPharma Group plc (NASDAQ:MREO) 2020 Interim Financial Results Conference Call September 29, 2020 8:00 AM ET Company Participants Steve Klass - IR, Burns McClellan Denise Scots-Knight - CEO Michael Wyzga - Interim CFO John Lewicki - Chief Scientific Officer Conference Call Participants Joseph Schwartz - SVB Leerink Operator Good morning ladies and gentlemen. Thank you for standing by and welcome to the Mereo BioPharma 2020 Interim Results Conference Call. At this time, all participants are in a list ...

Mereo BioPharma Group plc (NASDAQ:MREO) 2019 Interim Financial Results and Corporate Update Conference Call September 17, 2019 8:00 AM ET Company Participants Richard Jones – Chief Financial Officer Denise Scots-Knight – Chief Executive Officer Conference Call Participants Brian White – Cantor Fitzgerald Zoe Karamanoli – RBC Capital Markets Mick Cooper – Trinity Delta Operator Good morning ladies and gentlemen. Thank you for standing by and welcome to the Mereo BioPharma 2019 Interim Results Conference Call ...

| --- | --- | --- | --- | |-------|-------------------------|-------|-------| | | | | | | | | | | | | 2019 INTERIMS CORPORATE | | | DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. This presentation has been prepared by Mereo BioPharma Group plc (the "Company") solely for your information and for use at a presentation for th ...